Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Thursday, April 2, 2015, 86 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $348.46 to $37,984,375.00.

Highlighted Stocks Traded by Insiders:

Sucampo Pharmaceuticals (SCMP) - FREE Research Report

S&R Technology Holdings, LLC, who is 10% Owner at Sucampo Pharmaceuticals, sold 1.2 million shares at $14.00 on April 2, 2015. Following this transaction, the 10% Owner owned 20.3 million shares meaning that the stake was reduced by 5.53% with the 1.2 million-share transaction.

The shares most recently traded at $17.06, up $3.06, or 17.94% since the insider transaction. Historical insider transactions for Sucampo Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1.6 million
  • 12-Week # shares sold: 1.6 million
  • 24-Week # shares sold: 1.6 million

The average volume for Sucampo Pharmaceuticals has been 413,500 shares per day over the past 30 days. Sucampo Pharmaceuticals has a market cap of $703.6 million and is part of the health care sector and drugs industry. Shares are up 9.73% year-to-date as of the close of trading on Thursday.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs in the Americas, Europe, and Asia. The company has a P/E ratio of 54.0. Currently, there are 2 analysts who rate Sucampo Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCMP - FREE

TheStreet Quant Ratings rates Sucampo Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Sucampo Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Spectra Energy (SE) - FREE Research Report

Capps Allen C, who is Vice President and Controller at Spectra Energy, sold 1,313 shares at $36.27 on April 2, 2015. Following this transaction, the Vice President and Controller owned 1 shares meaning that the stake was reduced by 99.94% with the 1,313-share transaction.

The shares most recently traded at $36.60, up $0.33, or 0.9% since the insider transaction. Historical insider transactions for Spectra Energy go as follows:

  • 4-Week # shares bought: 6,200
  • 4-Week # shares sold: 1,313
  • 12-Week # shares bought: 6,200
  • 12-Week # shares sold: 12,063
  • 24-Week # shares bought: 6,200
  • 24-Week # shares sold: 20,813

The average volume for Spectra Energy has been 5.2 million shares per day over the past 30 days. Spectra Energy has a market cap of $24.2 billion and is part of the basic materials sector and energy industry. Shares are down 0.66% year-to-date as of the close of trading on Thursday.

Spectra Energy Corp, through its subsidiaries, owns and operates a portfolio of natural gas-related energy assets in North America. The stock currently has a dividend yield of 4.1%. The company has a P/E ratio of 22.4. Currently, there are 2 analysts who rate Spectra Energy a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SE - FREE

TheStreet Quant Ratings rates Spectra Energy as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Spectra Energy Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Centene (CNC) - FREE Research Report

Hunter Jesse N, who is EVP, Chief Bus. Dev. Officer at Centene, sold 5,000 shares at $69.66 on April 2, 2015. Following this transaction, the EVP, Chief Bus. Dev. Officer owned 220,450 shares meaning that the stake was reduced by 2.22% with the 5,000-share transaction.

The shares most recently traded at $70.48, up $0.82, or 1.16% since the insider transaction. Historical insider transactions for Centene go as follows:

  • 4-Week # shares bought: 17,600
  • 4-Week # shares sold: 25,000
  • 12-Week # shares bought: 17,600
  • 12-Week # shares sold: 25,000
  • 24-Week # shares bought: 17,600
  • 24-Week # shares sold: 60,900

The average volume for Centene has been 1.1 million shares per day over the past 30 days. Centene has a market cap of $8.4 billion and is part of the health care sector and health services industry. Shares are up 35.5% year-to-date as of the close of trading on Thursday.

Centene Corporation operates as a diversified, multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. It operates in two segments, Managed Care and Specialty Services. The company has a P/E ratio of 31.6. Currently, there are 7 analysts who rate Centene a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CNC - FREE

TheStreet Quant Ratings rates Centene as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Centene Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research

null